Dong-A ST announced on Jan. 10 that it signed a business agreement with Eleven Therapeutics to develop RNA-based gene therapies. The agreement was finalized at the J.P. Morgan Healthcare Conference in San Francisco on Jan. 9.
The collaboration will focus on discovering RNA therapies targeting fibrotic diseases using Eleven Therapeutics' TERA platform technology. This platform utilizes AI and machine learning to decode high-throughput RNA chemical modifications, aiding in the discovery of optimal xRNA drugs.
Dong-A ST has selected gene therapy as one of its key next-generation areas, continuously expanding its R&D capabilities from the field of synthetic new drugs to gene therapy.
Professor Yaniv Erlich, CEO and Co-founder of Eleven Therapeutics, expressed excitement about the partnership with Dong-A ST to address the unmet medical needs in fibrotic diseases. “Based on this partnership, we will strive to apply xRNA therapies across various disease areas,” he stated.
Park Jae-hong, president of Dong-A ST R&D, remarked, “Our collaboration with Eleven Therapeutics, known for its excellent technology, brings us closer to developing innovative RNA therapies. We are committed to transforming Dong-A ST into a leader centered on gene and cell therapies.”